PainReform Ltd. (NASDAQ:PRFX) Short Interest Down 63.7% in April

PainReform Ltd. (NASDAQ:PRFX) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 19,800 shares, a decline of 63.7% from the April 15th total of 54,600 shares. Based on an average daily volume of 138,900 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.2% of the company’s stock are short sold.

PainReform Trading Down 0.7 %

NASDAQ PRFX traded down $0.01 during trading on Friday, reaching $0.80. 2,632 shares of the company’s stock were exchanged, compared to its average volume of 106,302. The company’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $2.01. PainReform has a fifty-two week low of $0.69 and a fifty-two week high of $26.41.

Institutional Investors Weigh In On PainReform

An institutional investor recently bought a new position in PainReform stock. Armistice Capital LLC bought a new position in shares of PainReform Ltd. (NASDAQ:PRFX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 170,000 shares of the company’s stock, valued at approximately $468,000. Armistice Capital LLC owned about 10.90% of PainReform at the end of the most recent reporting period. 37.28% of the stock is currently owned by institutional investors.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.